Browse EX-10 agreements

HEALTHLYNKED CORPORATION

** **

Interim Chief Financial Officer Consulting Engagement Letter

** **

Date: July 10, 2026

** **

Mr. George O’Leary

Dear George,

HealthLynked Corporation (“HealthLynked” or the “Company”) is pleased to offer you the opportunity to serve as the Company’s Interim Chief Financial Officer during one of the most important periods in the Company’s history.

The purpose of this engagement is to provide executive financial leadership necessary to successfully complete the Company’s uplisting to the Nasdaq Capital Market, strengthen the Company’s financial infrastructure, and assist management in positioning HealthLynked for its next phase of growth and capital formation.

** **

Position

You will serve as Interim Chief Financial Officer of HealthLynked Corporation, reporting directly to the Chief Executive Officer and working closely with the Board of Directors.

…

CONFIDENTIAL

Karthik Gopalakrishnan

Vega Links Inc.

Chief Executive Officer

313 Bryant Court

Palo Alto, CA 94301

Re: Binding Letter of Intent for Acquisition of VEGA LINKS, Inc.

Dear Karthik,

This binding letter of intent (this “Letter”), together with the term sheet attached hereto, sets forth our mutual understanding regarding the terms of an acquisition of Vega Links Inc. and its affiliate(s) (collectively “VLI”) by Palomino Laboratories Inc. (“PLI”) in a transaction structured as an acquisition of all of the issued and outstanding shares of capital stock of VLI by PLI (the “Acquisition”). It is understood that any such transaction includes our mutual agreement on terms, and the entering into by VLI and PLI (each, a “Party” and collectively, the “Parties”) of definitive documents for the Acquisition and neither Party shall have any obligations other than as explicitly set forth herein unless and until a definitive agreement is entered into by and between VLI and PLI.

…

NON-BINDING LETfER OF INTENT

Date: July 3, 2026

To: Bio-Path Holdings, Inc.

Attn: Vik Grover

From: Farrington Capital Group LLC. and/or its designated affiliate, VantioBio and or Vantio Alpha Fund

Bio-Path Holdings, Inc. ("Bio-Path") and Farrington Capital Group LLC. and/or its designated affiliate, VantioBio and or Vantio Alpha Fund (collectively,"Buyer") are pleased to outline the principal terms of a proposed strategic transaction. This Letter of Intent is intended to provide a framework for diligence and negotiation concerning an exclusive out-license, asset acquisition, or similar transaction involving the DNAbilize platform and related Bio-Path programs, studies, data, know-how, intellectual property, regulatory materials, manufacturing information, and development documentation.

Transaction Scope

The contemplated transaction would include some or all of the following, to the extent owned, controlled, or licensable by Bio-Path:

•          Prexigebersen (BP1001), including related AML studies and supporting materials.

…

LETTER OF INTENT – PARTNERSHIP AND INVESTMENT BIO-PATH HOLDINGS, INC. – ALTFINS, J. S. A.

** **

Executive Summary

** **

Bio-Path Holdings, Inc. (OTC: BPTH) and altFINS are exploring a strategic partnership whereby BPTH establishes a Gen2 digital asset treasury - moving beyond passive Bitcoin accumulation toward a multi-asset, systematically managed cryptocurrency portfolio informed by altFINS’ institutional-grade on-chain fundamentals and technical analysis.

This proposal outlines the partnership structure, a phased treasury deployment plan, the specific altFINS capabilities BPTH would leverage, and how BPTH can differentiate itself from first-generation treasury adopters.

Metric	Value
Public companies holding crypto (mid-2026)	~200+
Collective holdings at peak	$180BN

Market Context: Gen1 vs. Gen2 Treasury Strategies

…

---

Exhibit 10.1

EXECUTION VERSION

AMENDMENT NO. 7 TO MASTER FRAMEWORK AGREEMENT

This AMENDMENT NO. 7 TO MASTER FRAMEWORK AGREEMENT (this “Amendment”), is made and entered into as of July 10, 2026 (the “Amendment Date”), by and among each of:

(A)

MUFG Bank, Ltd., a Japanese banking corporation (“MUFG”), as buyer (“Buyer”);

(B)

TXU Energy Retail Company LLC, a Texas limited liability company (“TXU”), as seller (the “Seller”);

(C)

each originator party hereto (each, an “Originator”; and together with the Seller, each a “Seller Party” and collectively, the “Seller Parties”);

(D)

TXU, as agent for the Seller Parties (in such capacity, the “Seller Party Agent”); and

(E)

solely with respect to Section 4.4 hereof, Vistra Operations Company LLC, as guarantor (the “Guarantor”),

…

***Execution Version ***

TERM LOAN CREDIT AGREEMENT

dated as of

July 15, 2026

Among

BAKER HUGHES HOLDINGS LLC,

as the Borrower,

BAKER HUGHES COMPANY,

as the Parent Guarantor,

The Lenders Party Hereto,

and

BANK OF AMERICA, N.A., as Administrative Agent

$1,000,000,000 TERM LOAN CREDIT FACILITY

BOFA SECURITIES, INC.,

as sole Bookrunner and sole Lead Arranger

---

**TABLE OF CONTENTS **

| | | | | | | | | ------------------------------------------ | - | ------------------------------------------------- | : | :--: | -: | - | | | | | | | | | | | | | | Page | | | | ARTICLE I DEFINITIONS | | | | | 1 | |

…

***Execution Version ***

TERM LOAN CREDIT AGREEMENT

dated as of

July 15, 2026

Among

BAKER HUGHES HOLDINGS LLC,

as the Borrower,

BAKER HUGHES COMPANY,

as the Parent Guarantor,

The Lenders Party Hereto,

and

UNICREDIT BANK GMBH, NEW YORK BRANCH, as Administrative Agent

$1,000,000,000 TERM LOAN CREDIT FACILITY

UNICREDIT BANK GMBH, NEW YORK BRANCH, as sole Bookrunner and sole Lead Arranger

---

**TABLE OF CONTENTS **

| | | | | | | | | ------------------------------------------ | - | ------------------------------------------------- | : | :--: | -: | - | | | | | | | | | | | | | | Page | | | | | | | | | | |

…

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

1.1

…

​

​

​

Exhibit 10.1

SEPARATION** **AGREEMENT

This Separation Agreement (this “Agreement”) is entered into by and between Glenn Reicin (“Executive”) andHarmony Biosciences Holdings,Inc. and Harmony Biosciences Management, Inc. (together the “Company”), effective as of July 16, 2026 (the “Effective Date”).

1.Separation.Effective as of July 16, 2026(the “Separation Date”), Executive’s employment with the Company and all of its affiliates shall terminate and Executive shall cease to be an employee of all of the foregoing. The parties hereto acknowledgeandagree that, effectiveas of the Separation Date, (i) thatcertain Employment Agreement, datedas of April 14, 2026,byandbetweenExecutiveandtheCompany(the“Employment Agreement”)shallterminate(exceptasotherwiseexpresslysetforthhereinandtherein)andtheCompany shall have no further obligations under the Employment Agreement; and (ii) Executive shall be deemed to have resigned from all offices and directorships held with the Company and its subsidiaries.

2.Separation* from Employment*.

…

SETTLEMENT AGREEMENT

This SETTLEMENT AGREEMENT (this “Agreement”) is entered into as of this 15th day of July, 2026 (the “Effective Date”), by and between Sadot Group Inc., a Nevada corporation (the “Company”), and Helena Global Investment Opportunities I Ltd., a Cayman Islands exempted company (the “Holder”). The Company and the Holder are each a “Party” and collectively the “Parties.”

RECITALS

…

** **

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING SUCH PORTIONS WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL PORTIONS (I) ARE NOT MATERIAL AND (II) FORUM MARKETS, INCORPORATED CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.

ENGINE SALE AND PURCHASE AGREEMENT

Dated as of July 13, 2026

BETWEEN

AERO ENGINE SOLUTIONS, INC.

as Seller

and

EURUS AEROSPACE TOKEN I LLC

as Buyer

with respect to the sale and purchase of one (1) CFM International model CFM56-7B aircraft engine bearing manufacturer’s serial number [***]

ENGINE SALE AND PURCHASE AGREEMENT

**THIS ENGINE SALE AND PURCHASE AGREEMENT **(this “Agreement”) is dated as of this 13th day of July 2026 and entered into by and between:

…

July 15, 2026

Lindsay Androski
Via E-mail

Re: Special Bonus Awards

Dear Lindsay:

Arbutus Biopharma, Inc. (together with Arbutus Biopharma Corporation, “Arbutus”) is writing to inform you of your eligibility to receive the following special cash bonus awards on the terms and conditions set forth in this letter agreement (this “Agreement”). Each of the payments described in the first three paragraphs of this Agreement is subject to the terms and conditions set forth in the fourth, fifth and sixth paragraphs of this Agreement.

…